granted patent: HEV antigenic peptide and methods

TitleHEV antigenic peptide and methods
Granted PatentUS 7204989
Granted Date2007-04-17
Priority Date2000-09-28 PCT/IB2000001393
1999-09-30 CA19992283538
Inventors
Issue Date2007
Citation
US Patent US 7204989. Washington, DC: US Patent and Trademark Office (USPTO), 2007 How to Cite?
AbstractA highly immunoreactive viral peptide, pE2, is disclosed which is derived from the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants which are only exposed when monomers of the peptide associate with one another through non-covalent interactions to naturally form homodimers. The novel pE2 peptide is proven to be highly reactive with sera from patients having current or past infection with HEV which suggests that the homodimer may mimic certain structural features of the HEV capsid protein. Furthermore, the antigenic activity of the pE2 peptide is strictly conformational in nature and therefore, exhibits immunochemical reactivity only when the peptide exists in a dimeric form. Consequently, the antigenic activity is lost upon dissociation of the dimers, but the activity is restored when the monomers reassociate to form dimers. Moreover, diagnostic methods useful in detecting and diagnosing HEV infection, and the use of a vaccine composition effective in preventing hepatitis E virus infection in which the novel pE2 peptide is utilized are also disclosed.
Persistent Identifierhttp://hdl.handle.net/10722/210543
References

 

DC FieldValueLanguage
dc.date.accessioned2015-06-17T07:04:17Z-
dc.date.available2015-06-17T07:04:17Z-
dc.date.issued2007-
dc.identifier.citationUS Patent US 7204989. Washington, DC: US Patent and Trademark Office (USPTO), 2007-
dc.identifier.urihttp://hdl.handle.net/10722/210543-
dc.description.abstractA highly immunoreactive viral peptide, pE2, is disclosed which is derived from the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants which are only exposed when monomers of the peptide associate with one another through non-covalent interactions to naturally form homodimers. The novel pE2 peptide is proven to be highly reactive with sera from patients having current or past infection with HEV which suggests that the homodimer may mimic certain structural features of the HEV capsid protein. Furthermore, the antigenic activity of the pE2 peptide is strictly conformational in nature and therefore, exhibits immunochemical reactivity only when the peptide exists in a dimeric form. Consequently, the antigenic activity is lost upon dissociation of the dimers, but the activity is restored when the monomers reassociate to form dimers. Moreover, diagnostic methods useful in detecting and diagnosing HEV infection, and the use of a vaccine composition effective in preventing hepatitis E virus infection in which the novel pE2 peptide is utilized are also disclosed.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License for public patent documents-
dc.titleHEV antigenic peptide and methods-
dc.typePatent-
dc.description.naturepublished_or_final_version-
dc.contributor.inventorIM STANLEY-
dc.contributor.inventorNG HON MUN-
dc.contributor.inventorZHANG JIZHONG-
patents.identifier.applicationUS 09/089292-
patents.identifier.grantedUS 7204989-
patents.description.assigneeYANG SHENG TANG COMPANY LTD [CN] -
patents.description.countryUnited States of America -
patents.date.granted2007-04-17-
dc.relation.referencesUS 6514690 (B1) 2003-02-04-
dc.relation.referencesUS 5686239 (A) 1997-11-11-
dc.relation.referencesUS 5741490 (A) 1998-04-21-
patents.identifier.hkutechidMicro-1999-00251-1-
patents.date.application2000-09-28-
patents.date.priority2000-09-28 PCT/IB2000001393-
patents.date.priority1999-09-30 CA19992283538-
patents.description.ccus-
patents.relation.familyMX PA02003270 (A) 2003-08-20-
patents.relation.familyCA 2283538 (A1) 2001-03-30-
patents.relation.familyWO 0122916 (A2) 2001-04-05 -
patents.relation.familyCN 1391579 (A) 2003-01-15 -
patents.relation.family C N1195774 (C) 2005-04-06-
patents.relation.familyEP 1461357 (A2) 2004-09-29 -
patents.relation.familyHK 1051544 (A1) 2006-01-13-
patents.relation.familyJP 2004500041 (A) 2004-01-08 -
patents.relation.familyBR 0014390 (A) 2003-09-30-
patents.relation.familyAU 7308200 (A) 2001-04-30-
patents.relation.family J P4641695 (B2) 2011-03-02-
patents.description.kindB1-
patents.typePatent_granted-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats